Asia-Pacific Iodinated Contrast Media in Interventional X-Ray Market By Route of Administration (Intravenous, Oral, Rectal, Others), Indication (Cardiology, Neurology, General Surgery, Oncology, Urology), Agent Type (Non-Ionic, Ionic), End User (Hospital, Specialty Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research & Academic Institutes), By Country (China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific), Market Trends and Forecast to 2027
Market Analysis and Insights: Asia-Pacific Iodinated Contrast Media in Interventional X-Ray Market
Asia-Pacific iodinated contrast media in interventional X-ray market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a stronger CAGR of 6.8% in the forecast period of 2020 to 2027 and expected to reach USD 702.87 million by 2027 from USD 419.54 million in 2019. Growing number of chronic diseases and wide acceptance of interventional X-ray in various diagnosis application are the major factors for the market growth.
Iodinated contrast media in interventional X-ray demand has been increased with rising chronic diseases across the region as compared to the past several years will accelerate the market growth. Advancement in interventional diagnostic methods and growing number of diagnostic centres will also impact positively on the demand of contrast agents used in interventional X-ray market. In addition. the rising number of imaging devices installations such as CT, X-ray and MRIs across the region led to higher demand for contrast agent especially iodinated contrast media.
This iodinated contrast media in interventional X-ray market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Iodinated Contrast Media in Interventional X-Ray Market Scope and Market Size
Asia-Pacific iodinated contrast media in interventional X-ray market is segmented of the basis of route of administration, indication, agent type and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Based on route of administration, iodinated contrast media in interventional X-ray market is segmented into oral, intravenous, rectal, others. Intravenous segment is dominating the market because intravenous iodinated contrast media is more popular and acceptable among caregiver and healthcare professionals due to their quick and efficient result as its is used in CT to help highlight blood vessels and to enhance the other various organs such as the brain, spine, liver and kidneys.
Based on agent type, iodinated contrast media in interventional X-ray market is segmented into ionic and non-ionic. Non-ionic segment is dominating in the market during the forecast period on account of growing acceptability and utilization in interventional diagnostics procedure especially in cardiovascular computed tomographic procedure.
Based on indication, iodinated contrast media in interventional X-ray market is segmented into cardiology, oncology, urology, general surgery and neurology. Cardiology segment is dominating the market due to the growing cases of cardiovascular diseases and blood disorders which further increases the demand to use interventional radiology diagnostic services.
Based on end user, the market is segmented into hospital, specialty clinics, diagnostic centers, ambulatory surgical centres, research & academic institutes. Hospital segment is dominating the market throughout the forecast period due to high volume of interventional radiology diagnostic procedure performed and increasing diagnosis seeking rate.
Iodinated Contrast Media in Interventional X-Ray Market Country Level Analysis
Asia-Pacific iodinated contrast media in interventional X-ray market is analysed and market size information is provided by country by route of administration, indication, agent type and end user as referenced above.
The countries covered in the iodinated contrast media in interventional X-ray market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific.
Asia-Pacific is growing with a highest growth rate due increasing incidence of cardiovascular diseases and cancer and surge in awareness regarding pre-diagnosis of such diseases and rising cases of trauma has boosted the demand of contrast agents. Furthermore, increasing research activities and launching innovative contrast agents has also propelled the demand for iodinated contrast agents. Additionally, improvement in healthcare infrastructure and use of cutting edge interventional equipment including digital X-Ray systems, CT also leads to the high patient volumes and high test demand.
The country section of the iodinated contrast media in interventional X-ray market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Adoption of Interventional Diagnosis in Cardiology
Iodinated contrast media in interventional X-ray market report also provides you with detailed market analysis for every country growth in medical industry with iodinated contrast media in interventional X-ray sales, components sales, impact of technological development in iodinated contrast media in interventional X-ray and changes in regulatory scenarios with their support for the iodinated contrast media in interventional X-ray market. The data is available for historic period 2010 to 2018.
Competitive Landscape and Iodinated Contrast Media in Interventional X-Ray Market Share Analysis
Asia-Pacific iodinated contrast media in interventional X-ray market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Asia-Pacific iodinated contrast media in interventional X-ray market.
The major players covered in the report are Bayer AG, Iso-Tex Diagnostics, Inc., Bracco Diagnostic Inc., Novalek Pharmaceuticals Pvt. Ltd., iMAX, Taejoon Pharm, Unijules life science Ltd, General Electric, Guerbet LLC, J.B.Chemicals & Pharmaceuticals Ltd among others players domestic and global. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
- In June 2019, General Electric and Daiichi Sankyo Company did an agreement that Daiichi Sankyo to transfer authorization of marketing rights for four diagnostic imaging agents in Japan to GE Healthcare. After completing this agreement the company expand their diagnostic imaging agents in the Japan. This will help company to expand their business in the market.
- In July 2018, General Electric announced that they have launched ready-to-drink oral solution of iodinated contrast agent which can help physicians improving the visualization of diagnostic abdominal gastrointestinal tract. With this new formulation of contrast agent the company enhanced its choice of options for oral contrast agent which is available to radiologists and patients.
Partnership, expansion and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for iodinated contrast media in interventional X-ray through expanded model range.